GlassScriptPhysician profile
Ronald S Suh
NPI 1164436523
$24,372.95
in general payments reported to CMS, 2019-2025
55 companies · $2,373 in 2025
The $2,373 reported for 2025 was more than what 83% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $917 · 2021: $335 · 2022: $1,461 · 2023: $1,937 · 2024: $1,851 · 2025: $2,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,925 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,925.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $236.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $14,243.71 | 2019-2024 | Aveed, Xiaflex |
| Avyxa Pharma, LLC | $1,000.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $996.07 | 2019-2025 | |
| Janssen Biotech, INC. | $874.47 | 2019-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $577.25 | 2019-2024 | Myrbetriq |
| Sumitomo Pharma America, INC. | $533.10 | 2023-2025 | Orgovyx, Gemtesa |
| Dendreon Pharmaceuticals LLC | $509.34 | 2019-2025 | Provenge |
| Pfizer INC. | $456.77 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $410.49 | 2022-2025 | |
| Coloplast Corp | $348.01 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $285.14 | 2021-2025 | Prolaris |
| Ferring Pharmaceuticals INC. | $263.40 | 2019-2023 | Adstiladrin |
| Abbvie INC. | $232.83 | 2019-2024 | Lupron Depot, Botox |
| Amgen INC. | $219.08 | 2019-2021 | |
| Genzyme Corporation | $215.40 | 2019-2023 |
Show all 50 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Suh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.